Stents Bioresorbable

This channel includes news and new technology innovations for bioresorbable stents (BRS). These devices are also referred to as bioabsorbable stents, bioresorbable scaffolds and dissolving stents. BRS are designed as an alternative to permanent metallic stent implants, which cause issues in a small number of patients with in-stent restenosis, late-stent thrombosis and require use of long-term antiplatelet therapy. Metallic stents also cause issues with CT and MRI imaging and may prevent future options for coronary bypass graft (CABG) surgery. BRS are supposed to remove avoid these issues by dissolving and disappearing from the vessel after a period of 2-4 years. This, returns the vessel to its natural state and allows for the return of vasodilatation and vasoconstriction. BRS have had some issues in clinical trials not being able to match the performance of standard metallic drug eluting stents (DES) because of their thick stent struts. Newer generation BRS are in development with struts smaller than 100 micros, with will be closer to those of current generation metallic stents

 

DESolve Nx Pivotal Trial Bioresorbable Coronary Stent Elixir Cath Lab
Feature | October 30, 2012
October 30, 2012 — Elixir Medical Corp. said enrollment is complete in its 120-patient, pivotal clinical trial...
Feature | October 19, 2012
October 19, 2012 — The 24th Transcatheter Cardiovascular Therapeutics (TCT) conference, sponsored by the Cardiovascular...
DESolve Bioresorbable Coronary Scaffold System Clinical Trial
News | October 19, 2012
October 19, 2012 — Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices...
Abbott Bioabsorbable Stent  Absorb
Feature | September 28, 2012
September 28, 2012 — The world’s first drug-eluting bioabsorbable vascular scaffold has been launched and will...
Abbott bioresorbable Absorb stent BVS
Feature | September 26, 2012
September 26, 2012 — Abbott Vascular this week began its international launch of the Absorb coronary stent, the world's...
News | August 14, 2012
August 14, 2012 — The U.S. Food and Drug Administration (FDA) is hosting a public workshop that examines use of...
News | July 17, 2012
July 17, 2012 — Arterial Remodeling Technologies (ART) reported that they have achieved a medical milestone with its...
News | July 16, 2012
July 16, 2012 — Reva Medical Inc. announced it completed clinical enrollment with the ReZolve drug-eluting...
News | April 16, 2012
April 16, 2012 - 480 Biomedical announced that it has initiated the first human trial of its groundbreaking Stanza self...
News | April 05, 2012
April 5, 2012 — Arterial Remodeling Technologies (ART) reported yesterday that in vivo data strongly suggest that its...
Feature | March 27, 2012
March 27, 2012 — Biodegradable polymer drug-eluting stents (DES) provide better long-term safety and efficacy than...
Feature | March 16, 2012 | Mark Paquin
April 15, 2012, will mark the 10th anniversary of the approval of the first drug-eluting stent (DES). Ten years ago,...
News | December 22, 2011
December 22, 2011 ­– Abbott today announced the initiation of ESPRIT I, a first-of-its-kind clinical trial in Europe...
News | December 09, 2011
December 9, 2011 — Abbott announced Thursday the initiation of ABSORB II, the first randomized, controlled, multi-...
News | November 15, 2011
November 15, 2011 – Abbott announced positive long-term data from the two-stage ABSORB trial, which is evaluating the...